Adherium Highlights Milestones Achieved in Advance of 2018

21 Dec 2017 San Mateo, CA – December 20, 2017: Adherium (ASX: ADR), a digital health company that improves medication adherence and patient outcomes, today highlighted milestones achieved in advance of 2018. “As we conclude December and the calendar year, we are accelerating realization of our vision of stronger partnerships between patients and physicians, facilitated by […]

AmpliPhi Biosciences Provides Corporate and Strategic Update

 Under single-patient expanded access program, seven patients with serious and life-threatening infections, not responding to antibiotics, were treated with AB-SA01 or AB-PA01 in 2017. Company plans to present topline results in early 2018  Company expects to continue its expanded access clinical strategy in 2018, review data with FDA in mid-2018 and initiate Phase 2 or […]

China Medical System Holdings Limited invests £3.0 million in Destiny Pharma

Posted on 01/12/2017 THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) […]

AVITA Announces Office Transitions in Australia and the UK

Avita Announces Office Transitions in Australia and the UK Decision Optimizes Access to Strategic Markets to Support Long-Term Growth Strategy Valencia, CA, USA, Perth, Australia and London, United Kingdom, 29 November 2017 — Avita Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company with a platform technology creating opportunities in burn and wound care, and […]

AmpliPhi Biosciences Reports Third Quarter 2017 Financial Results and Business Highlights

Six patients with life-threatening S. aureus or P. aeruginosa infections treated to date with AB-SA01 or AB-PA01 under expanded access in the U.S. and Australia  Second clinical institution to treat patients with AB-SA01 or AB-PA01 under expanded access is now operational  First-in-human intravenous dosing of AB-SA01 as part of expanded access treatment of a patient […]

Avita Medical – Rights Issue Raises $12.4 Million

Avita Medical announces Rights Issue raises $12.4 million Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, — Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the results of the Non-Renounceable Rights Issue. The Board of Avita Medical Limited is pleased […]

BioScience Managers Expands Team, Adding Significant New International Expertise

London, UK and Melbourne, Australia, 30 October 2017 – Leading healthcare investment specialist BioScience Managers Limited (BioScience Managers), has announced the expansion of its team with the addition of three new directors with broad sector and geographic experience – Dr Michael Perry as a Director, Dennis Purcell as a Director and Senior Expert Advisor, and […]

Avita Medical and BARDA Execute a US$24.3m Contract Option

Valencia, CA, USA, Perth, Australia and London, United Kingdom, 21 September 2017 — Avita Medical (ASX: AVH), (OTCQX: AVMXY),  – link here a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the execution of an expanded contract option valued at approximately US$24.3 million. This newly executed contract option establishes […]

Adherium Releases Next Generation Adherence Monitor, SmartTurbo Model 4, for AstraZeneca’s Turbuhaler

Adherium today announced it has released SmartTurbo Model 4, the next generation of the company’s adherence monitoring technology, for AstraZeneca’s Turbuhaler medication. SmartTurbo Model 4 includes usability improvements to make the installation and removal of the Turbuhaler easier for older patients with COPD. The device also features a series of new larger buttons that help patients easily access new optional […]

AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus

A patient suffering from a life-threatening staphylococcal endocarditis received AB-SA01 under expanded access regulatory guidelines CATEGORY: Featured Monday, September 11, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We continue implementation of our strategy to work with leading infectious disease physicians in the United States and Australia and […]